Spatial Distribution of (R)-salbutamol in Rat Brain Following Nasal and Intravenous Administration Using DESI-MS

Abstract

Recent studies have shown that β2-Adrenoreceptor is a regulator of the a-synuclein gene driving risk of Parkinson’s disease. The β2-AR agonist (R)-salbutamol, eutomer of rac-salbutamol, may hold therapeutic potential for Parkinson’s disease (PD) following nasal administration. In this study, we use desorption electrospray ionization mass spectrometry (DESI-MS) to analyze spatial distribution of (R)-salbutamol in rat brain following nasal and intravenous administration. Here, we report that (R)-salbutamol efficiently deliver to the brain and had more drug dosage exposure in rat’s brain through nasal route administration than that of intravenous route administration. In conclusion, administering (R)-salbutamol through nasal route of administration may hold advantages in improving spatial distribution and increased exposure of drug in brain.

Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing

“…Conducting longitudinal analyses in 4 million Norwegians, they found that salbutamol (a β2AR agonist) reduced the risk of Parkinson's disease 254 . Animal studies revealed that terbutaline can pass the BBB of rabbits and salbutamol can pass the BBB of rats 255,256 . Future randomized controlled trials are needed to test clinical benefits of terbutaline and salbutamol in individuals with ALS or Parkinson's disease.…”